Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.

Interleukin 2 (IL-2) administered at low doses for prolonged periods can markedly expand the number of CD56(+) natural killer (NK) cells in patients with metastatic cancer. The cytotoxic capacity of NK cells obtained from patients receiving IL-2 in vivo can be dramatically augmented by additional exposure to IL-2 in vitro. These observations formed the basis of a clinical trial in which patients with metastatic cancer were treated with low-dose continuous daily infusions of IL-2 to increase the number of their NK cells in conjunction with intermittent boluses of additional IL-2 to stimulate this expanded pool of cytotoxic cells. Twenty-three patients were registered to receive IL-2 at 4.5 x 10(5) units/m2/day for 8 weeks by continuous i.v. infusion. After 4 weeks of "priming" with low-dose continuous infusion IL-2, cohorts of three to five patients received 5 weekly 2-h boluses of IL-2 at doses ranging from 2.5 x 10(5) units/m2 to 1.0 x 10(6) units/m2. Low-dose continuous infusion IL-2 was usually well tolerated; 2-h bolus infusions of IL-2 were often associated with high fevers and constitutional symptoms that resolved after several hours. Low-dose continuous infusion IL-2 resulted in the progressive expansion of circulating CD56(+)CD3(-) NK cells. In contrast, each bolus infusion of IL-2 resulted in an immediate dramatic decrease in both the number of NK cells and activated T lymphocytes with recovery noted within 24 h. Bolus doses of IL-2 as low as 2.5 x 10(5) units/m2 were capable of producing these effects. Cytolytic activity against NK-sensitive and -resistant targets correlated with the presence of circulating activated NK cells. Our results demonstrate that NK cells expanded by low-dose continuous infusions of IL-2 can be further activated in vivo by exposure to very low doses of IL-2 as a 2-h i.v. bolus. This capacity to manipulate human NK cells in vivo through varying the dose and schedule of IL-2 administration may help in defining the therapeutic potential of these cytotoxic effectors in the treatment of both neoplastic and infectious diseases.

[1]  J. Ritz,et al.  Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. , 1994, Blood.

[2]  Kendall A. Smith,et al.  Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells , 1994, The Journal of experimental medicine.

[3]  S. Voss,et al.  Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. , 1994, Blood.

[4]  K. Smith,et al.  Lowest dose interleukin-2 immunotherapy. , 1993, Blood.

[5]  W. Leonard,et al.  Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. , 1993, Journal of immunology.

[6]  M. Caligiuri,et al.  Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. , 1993, The Journal of clinical investigation.

[7]  L. Bergmann,et al.  Rapid cytokine release in cancer patients treated with interleukin-2. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[8]  J. Ritz,et al.  Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF , 1992, The Journal of experimental medicine.

[9]  J. Ritz,et al.  Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.

[10]  M. Caligiuri,et al.  Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Weller,et al.  Human eosinophils express functional interleukin 2 receptors. , 1991, The Journal of clinical investigation.

[12]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Kaplan,et al.  The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy , 1991, The Journal of experimental medicine.

[14]  M. Atkins,et al.  Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments] , 1990 .

[15]  M. Caligiuri,et al.  Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. , 1990, Journal of immunology.

[16]  L. Barnett,et al.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.

[17]  L. Lanier,et al.  Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo , 1990, The Journal of experimental medicine.

[18]  D. Longo,et al.  Expression and role of p75 interleukin 2 receptor on human monocytes , 1990, The Journal of experimental medicine.

[19]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[20]  M. Atkins,et al.  Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. , 1990, Blood.

[21]  T. Whiteside,et al.  The role of natural killer cells in human disease. , 1989, Clinical immunology and immunopathology.

[22]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[23]  R. Fisher,et al.  Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Fisher,et al.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. , 1988, Annals of internal medicine.

[25]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[26]  P. Frost,et al.  Natural killer cell activity of prostatic cancer patients. , 1987, Cancer investigation.

[27]  K. Anderson,et al.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. , 1986, Blood.